New hope for treatment of Alzheimer's disease

July 15, 2014, Douglas Mental Health University Institute

Judes Poirier, PhD, C.Q., from the Douglas Mental Health Institute and McGill University in Montréal (Canada) and his team have discovered that a relatively frequent genetic variant actually conveys significant protection against the common form of Alzheimer's disease and can delay the onset of the disease by as much as 4 years. This discovery opens new avenues for treatment against this devastating disease.

Dr. Poirier announced his findings as the annual Alzheimer's Association International Conference was taking place in Copenhagen. This large-scale study identified naturally occurring genetic variants that provide protection against the common form of Alzheimer's disease, with the goal of identifying specific biological processes amenable to pharmaceutical interventions.

"We found that specific genetic variants in a gene called HMG CoA reductase which normally regulates cholesterol production and mobilization in the brain can interfere with, and delay the onset of Alzheimer's disease by nearly 4 years. This is an exciting breakthrough in a field where successes have been scarce these past few years" says Dr. Poirier, whose previous research led to the discovery that a genetic variant was formally associated with the common form of Alzheimer's disease.

"These latest genetic results from Dr. Poirier's team are an important step forward in the understanding of Alzheimer's disease neurobiology, and also the use of genetics to identify an interesting new molecular target that is amenable to therapeutic development" added Brigitte Kieffer, Scientific Director of the Research Centre of the Douglas Mental Health University Institute."

A different approach

Over the past two decades, research efforts around the globe have focused on identifying genetic and environmental factors responsible for causing or accelerating the progression of the common form of Alzheimer's disease. However, little was known about possible protective genetic factors that can delay or even prevent the disease onset in humans. It is well documented that a subset of older individuals who happen to be carriers of predisposing genetic factors for the common form of Alzheimer's manage to escape the and live long and productive lives without any memory problems until their 90's.

Explore further: Babies with Down syndrome could help delay the onset of Alzheimer's disease

Related Stories

Babies with Down syndrome could help delay the onset of Alzheimer's disease

July 3, 2014
Alzheimer's disease is typically a disease of later life, and age is the biggest known risk factor for the condition. But babies with Down syndrome, who always develop brains like those with Alzheimer's later in life, don't ...

New risk gene illuminates Alzheimer's disease

February 25, 2014
A team of international scientists, including a researcher from Simon Fraser University, has isolated a gene thought to play a causal role in the development of Alzheimer's disease. The Proceedings of the National Academy ...

Researchers identify variation in gene PLD3 can increase risk of late-onset Alzheimer’s disease

December 24, 2013
(Medical Xpress)—A new study, part-funded by the Medical Research Council (MRC), the Wellcome Trust and Alzheimer's Research UK, has shown that a fault in a gene called phospholipase D3 (PLD3) can contribute to the overproduction ...

Gene discovery offers new path for Alzheimer's research

July 9, 2013
A new gene variant has been linked to Alzheimer's disease, and this association is strongest among elderly blacks.

Study explores genetics behind Alzheimer's resiliency

May 2, 2014
Autopsies have revealed that some individuals develop the cellular changes indicative of Alzheimer's disease without ever showing clinical symptoms in their lifetime.

Compounded outcomes associated with comorbid Alzheimer's disease, cerebrovascular disease

July 3, 2014
Researchers from the Sanders-Brown Center on Aging at the University of Kentucky have been able to confirm anecdotal information on patients with both Alzheimer's disease (AD) and cerebrovascular disease (CVD) using mouse ...

Recommended for you

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.